PapersPMID:22894890
Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study.
What moved
1 findingHow to read these marks →“After controlling for baseline values, we observed a significantly greater reduction over time in total HAM-D scores for chamomile versus placebo in all subjects (p<0.05).”
- Study
- RCT
- Duration
- 8 weeks
- Dose studied
- 220 mg capsules, 1 daily in week 1, 2 daily in week 2, titrated by HAM-A response to up to 5 daily (1100 mg/day) in weeks 5-8
- Population
- adults with mild to moderate generalized anxiety disorder (DSM-IV), some with comorbid or past depression; exploratory reanalysis of a randomized placebo-controlled trial
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Outpatients with mild to moderate generalized anxiety disorder (exploratory reanalysis of the 2009 chamomile trial), with subgroups of current co-morbid depression, past depression, and no current or past depression
- Participants
- 57
- Comparator
- placebo
- Duration
- 56 days
- Endpoints measured
- 7